×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update
Yahoo Finance
Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024.
1 day ago
Atyr Pharma: Q1 Earnings Snapshot
Houston Chronicle
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (LIFE) on Thursday reported a loss...
1 day ago
aTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200 Day Moving Average of $1.55
Defense World
Read aTyr Pharma (NASDAQ:LIFE) Stock Passes Above 200 Day Moving Average of $1.55 at Defense World.
19 hours ago
aTyr Pharma (NASDAQ:LIFE) Share Price Crosses Above Two Hundred Day Moving Average of $1.55
MarketBeat
aTyr Pharma (NASDAQ:LIFE) Stock Price Crosses Above 200 Day Moving Average of $1.55.
14 hours ago
aTyr Pharma to Participate in April Investor Conferences
GlobeNewswire
(Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary...
1 month ago
aTyr Pharma earnings beat, revenue topped estimates
Investing.com India
Investing.com - aTyr Pharma (NASDAQ: LIFE ) reported first quarter EPS of $-0.230, better than the analyst estimate of $-0.240.
16 hours ago
Bullish aTyr Pharma Insider Buying Worth US$514.6k Yet To Pay Off
Simply Wall Street
Insiders who bought US$514.6k worth of aTyr Pharma, Inc.'s ( NASDAQ:LIFE ) stock at an average buy price of US$2.10...
2 weeks ago
aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k
Yahoo Finance
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it happened in aTyr Pharma,...
2 weeks ago
aTyr Pharma doses first patient in systemic sclerosis trial
Clinical Trials Arena
aTyr Pharma has dosed the first subject in the Phase II EFZO-CONNECT trial of efzofitimod to treat systemic sclerosis (ILD).
6 months ago
After losing 23% in the past year, aTyr Pharma, Inc. (NASDAQ:LIFE) institutional owners must be relieved by the recent ...
Yahoo Finance
Key Insights · Institutions' substantial holdings in aTyr Pharma implies that they have significant influence over the company's share price · A...
3 months ago